within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DX18_Linsidomine;

model Linsidomine
  extends Pharmacolibrary.Drugs.ATC.C.C01DX18;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01DX18</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Linsidomine, also known as SIN-1, is a vasodilator and a prodrug that releases nitric oxide (NO) upon metabolism. It was developed for the treatment of angina pectoris and other cardiovascular conditions due to its ability to induce vasodilation. Linsidomine is not widely used today and is not an approved drug in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for intravenous administration in healthy adult volunteers, as direct PK parameter publications for linsidomine are not available.</p><h4>References</h4><ol><li><p>Sennesael, J, et al., &amp; Gaertner, W (1993). Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 31(11) 533–541. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8294165/&quot;>https://pubmed.ncbi.nlm.nih.gov/8294165</a></p></li><li><p>Foucher-Lavergne, A, et al., &amp; Beaufils, P (1993). Hemodynamics, tolerability, and pharmacokinetics of linsidomine (SIN-1) infusion during the acute phase of uncomplicated myocardial infarction. <i>Journal of cardiovascular pharmacology</i> 22(6) 779–784. DOI:<a href=&quot;https://doi.org/10.1097/00005344-199312000-00001&quot;>10.1097/00005344-199312000-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7509893/&quot;>https://pubmed.ncbi.nlm.nih.gov/7509893</a></p></li><li><p>Ostrowski, J, &amp; Resag, K (1985). Pharmacokinetics of molsidomine in humans. <i>American heart journal</i> 109(3 Pt 2) 641–643. DOI:<a href=&quot;https://doi.org/10.1016/0002-8703(85)90670-2&quot;>10.1016/0002-8703(85)90670-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3838399/&quot;>https://pubmed.ncbi.nlm.nih.gov/3838399</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Linsidomine;
